Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Senexis and O2H or Oxygen Healthcare have signed agreement under which O2H will provide synthetic and computational chemistry services to the drug discovery programs at Senexis on an full time equivalent or FTE basis.
Subscribe to our email newsletter
David Scopes, chief scientific officer of Senexis, said: “We believe our collaboration with O2H leverages the complementary expertise of both organisations and will benefit our search for new therapeutics to treat ageing-related diseases by helping Senexis increase the return on its chemistry research budget.”